Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2a Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or is Refractory to Rituximab

Next Previous
Trial Profile

Phase 1/2a Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or is Refractory to Rituximab

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acalabrutinib (Primary) ; BI 1206 (Primary) ; BI 1206 (Primary) ; Rituximab
  • Indications B-cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors BioInvent International

Most Recent Events

  • 08 Dec 2025 According to a BioInvent International media release, among 15 evaluable patients in the safety run-in (data cut-off December 1, 2025), no differences in safety or efficacy were observed between the two dose levels, supporting continued enrollment into the trial's expansion phase.
  • 08 Dec 2025 According to a BioInvent International media release, company announced the presentation of new data from the safety run-in portion of the trial evaluating BI-1206, in combination with rituximab and Calquence (acalabrutinib) for the treatment of non-Hodgkin's lymphoma (NHL) at the 2025 American Society of Hematology (ASH) Annual Meeting in Orlando, Florida.
  • 08 Dec 2025 Results presented in a BioInvent International media release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top